生醫施政總檢討 五面向把脈 2017-05-04 01:58 經濟日報 記者黃文奇/台北報導 總統府昨(3)日拍板,將於5月底對生醫產業展開施政總檢討,
Pages
Thursday, May 4, 2017
(台灣生醫發展路障) 總統府: …5月底..一次清除 !!!
(JCO: pleural mesothelioma治療) 北極星cisplatin (75 mg/m2)+ pemetrexed (500 mg/m2)+.ADI-PEG20
北極星肺間皮癌聯合用藥 臨床結果佳(中央社記者韓婷婷台北2017年5月3日電)
[Epub ahead of print]
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. J Clin Oncol. 2017 Apr 7:JCO2016713230. doi: 10.1200/JCO.2016.71.3230.
Purpose Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) -negative tumors by converting arginine to citrulline and ammonia. The main aim of this study was to determine the recommended dose, safety, and tolerability of ADI-PEG 20, cisplatin, and pemetrexed in patients with ASS1-deficient malignant pleural mesothelioma (MPM) or non-small-cell lung cancer (NSCLC). Patients and Methods Using a 3 + 3 + 3 dose-escalation study, nine chemotherapy-naïve patients (five MPM, four NSCLC) received weekly ADI-PEG 20 doses of 18 mg/m2, 27 mg/m2, or 36 mg/m2, together with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 which were given every three weeks (maximum of six cycles). Patients achieving stable disease or better could continue ADI-PEG 20 monotherapy until disease progression or withdrawal. Adverse events were assessed by Common Terminology Criteria for Adverse Events version 4.03, and pharmacodynamics and immunogenicity were also evaluated. Tumor response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for NSCLC and by modified RECIST criteria for MPM. Results No dose-limiting toxicities were reported; nine of 38 reported adverse events (all grade 1 or 2) were related to ADI-PEG 20. Circulating arginine concentrations declined rapidly, and citrulline levels increased; both changes persisted at 18 weeks. Partial responses were observed in seven of nine patients (78%), including three with either sarcomatoid or biphasic MPM. Conclusion Target engagement with depletion of arginine was maintained throughout treatment with no dose-limiting toxicities. In this biomarker-selected group of patients with ASS1-deficient cancers, clinical activity was observed in patients with poor-prognosis tumors. Therefore, we recommend a dose for future studies of weekly ADI-PEG 20 36 mg/m2 plus three-weekly cisplatin 75 mg/m2 and pemetrexed 500 mg/m2.
(中醫大) 2017年Q2 醫療同意書 數位簽署 完工 !
中國醫藥大學附設醫院 通過 HIMSS EMRAM 六級電子病歷國際認證 【勁報記者張亞痕/臺中報導】2017年4月12日,來自美國的
關於中國醫藥大學附設醫院 中國醫藥大學附設醫院創立於1980年,是臺灣第一家中、
關於HIMSS Analytics HIMSS Analytics為美國醫療資訊與管理系統學會(Health
關於HIMSS大中華區HIMSS Greater China(大中華區)建立於2014年初,是HIMSS下屬負
(生醫募資) 國際製藥公司 類似 電影製片商
藥廠找金主 手法很好萊塢 2017-05-04 01:06 經濟日報 編譯葉亭均/綜合外電 眼看投入研發的報酬日益下滑,不少製藥大廠正師法好萊塢策略,
中醫大 陳書怡: (便秘問題) 蜂蜜加優格效果不錯 !!!
蜂蜜減產7成 蜂農憂假蜜混充以假亂真 2017-05-03〔記者蔡淑媛/台中報導〕
智擎 42億 達標金2020年內 全入帳 !!!
智擎股利配發4.5元 2017-05-04 00:29 經濟日報 記者黃文奇/台北報導 智擎(4162)昨(3)日董事會通過將配發2元股票股利及2.
生醫產業 染政治/政黨 顏色?
生策會搭橋 打破藍綠框架 2017-05-04 01:58 經濟日報 記者黃文奇/台北報導 總統府昨(3)日拍板將在月底召開「生醫產業經營者大會」,
展旺 新營運長 洪堯樂 (美時副總)
展旺:公告本公司重要營運主管異動 鉅亨網新聞中心※來源:台灣證券交易所2017/05/03第二
瑞寶 豬二價疫苗 (藍耳病+環狀病毒) 三價疫苗 (藍耳病+環狀病毒+豬瘟)
瑞寶開發多價疫苗 競爭力強 2017-05-03 20:01 經濟日報 蔡尚勳 台灣豬肉也是國人主要食用肉類來源,2015年台灣豬隻在養頭數
台灣東洋 解除競業: 胡宇方 (研發副總)
台灣東洋 發言日期106/05/03發言時間17:30:36 發言人張國江發言人職稱財務長發言人電話26525999-
(浩鼎案) …翁啟惠持浩鼎股票 僅利害關係 不見得 利益衝突
買浩鼎股票送女兒 翁啟惠:檢方曲解本意 2017-05-03 12:57中央社 台北3日電 士林地院今天審理浩鼎案,被告、前中研院長翁啟惠說,他出資買3
(肝細胞) 中科院: 多能幹細胞 多次相互轉換 新突破epithelial–mesenchymal–epithelial
與陰陽理念重合 我國科學家揭示幹細胞分化新機制 北京新浪網 (2017-05-03 21:35) 新華社北京5月3日電(記者 董瑞豐)記者3日從中國科學院獲悉,
A sequential EMT-MET mechanism drives the differentiation of human embryonic stem cells towards hepatocytes. Nature Communications 8, Article number: 15166 (2017) Abstract Reprogramming has been shown to involve EMT–MET; however, its role in cell differentiation is unclear. We report here that in vitro differentiation of hESCs to hepatic lineage undergoes a sequential EMT–MET with an obligatory intermediate mesenchymal phase. Gene expression analysis reveals that Activin A-induced formation of definitive endoderm (DE) accompanies a synchronous EMT mediated by autocrine TGFβ signalling followed by a MET process. Pharmacological inhibition of TGFβ signalling blocks the EMT as well as DE formation. We then identify SNAI1 as the key EMT transcriptional factor required for the specification of DE. Genetic ablation of SNAI1 in hESCs does not affect the maintenance of pluripotency or neural differentiation, but completely disrupts the formation of DE. These results reveal a critical mesenchymal phase during the acquisition of DE, highlighting a role for sequential EMT–METs in both differentiation and reprogramming. Introduction Reprogramming of somatic cells into pluripotent ones with defined factors not only provides a new way to generate functional cells for regenerative medicine, but also establishes a new paradigm for cell fate decisions. For the latter, a cell at a terminally differentiated state can be restored back to pluripotency under well-defined conditions fully observable through molecular and cellular tools. Indeed, the reprogramming process has been analysed in great detail to reveal novel insights into the mechanism of cell fate changes. Of particular interest is the acquisition of epithelial characteristics from mesenchymal mouse embryonic fibroblasts (MEFs) commonly employed as starting cells in reprogramming experiments. Termed the mesenchymal to epithelial transition (MET), we and others have described the MET as marking the earliest cellular change upon the simultaneous transduction of reprogramming factors POU5F1 (OCT4), SOX2, KLF4 and MYC or OSKM into MEFs. However, when delivered sequentially as OK+M+S, they initiate a sequential epithelial to mesenchymal transition (EMT)-MET process that drives reprogramming more efficiently than the simultaneous approach, suggesting that the switching between mesenchymal and epithelial fates underlies the reprogramming process, that is, the acquisition of pluripotency. We then speculated that such a sequential EMT–MET process might underlie cell fate decisions in other situations such as differentiation, generally viewed as the reversal of reprogramming with the loss of pluripotency. Herein, we report that a similar epithelial–mesenchymal–
精準醫學 學術/商業 優質模範生: 慧智基因 (產科備戰: 基因資料庫 診斷>1000基因異常)
慧智基因去年每股賺2.65元 年增1.6倍 2017-05-03 16:37 中央社 記者韓婷婷台北3日電 興櫃生技股慧智基因,去年繳出高成長、高毛利及高獲利「三高」
薇佳(歐漾國際) 鋁管保養品 無塑化劑/防腐劑MI/MCI/Paraben孕婦安心
醫美保養品牌「薇佳」鋁管包裝杜絕塑化劑孕期更安心!中央網路報 (2017-05-02 16:40) 薇佳 微晶3D全能淡斑精華產品圖懷孕期間恐會有痘痘、
保養品含塑化劑? 孕期保養品專家教你怎麼挑有些女性在懷孕期間,胎兒為男生時,
薇佳藥品級「鋁管」包裝 杜絕塑化劑危機 提供孕婦安心保養選擇 歐漾國際旗下醫美保養品牌「薇佳」,秉持簡單、安全、
(食藥好文網) 衛福部 強化網民互動
「食藥安全 搜好文」記者會資料來源:衛生福利部建檔日期:106-05-
謠言終結機 解決網友迷惑「謠言終結機」
掃一掃QR-code 直接發問好容易 食藥署特別建置「食藥好文網」網站,
PlexBio (博錸) 新CFO: IFRS專家 葉麗碧
博錸生技再度延攬專家 展限企圖心 中央社-2017年05月03日 (中央社訊息服務20170503 11:03:46)博錸生技(6572)延攬IFRS專家葉麗碧
精華 產能滿載 2017年將5.18億 建12條 產線 (1000~1200萬片/條)/ 金可將增4條!!
隱形眼鏡雙雄 下半年擴產 2017-05-02 15:02 聯合晚報 記者嚴雅芳/台北報導 隱形眼鏡雙雄下半年都有擴產計畫,精華(1565)
澳優乳業()布局全球21國 (獨漏台灣)擬鎖定未上市公司 合作 !!!
晟德加碼台灣 收購乳品通路 2017-05-02 04:53經濟日報 記者黃文奇/台北報導晟德集團旗下的澳優乳業近期又有新動作,
(王昶皓 醫師) 口服C肝新藥CP值相當高 !! 療效較短 肝毒較大小心使用
C肝早治早好 別因等待錯失良機 健康醫療網 2017/05/03 (健康醫療網/記者林怡亭報導) C肝口服新藥價格昂貴,為了清除C肝病毒,部分患者透過網路平台
不治療C肝 三成患者20年恐成肝癌 王昶皓醫師指出,如果從藥物經濟學來看,C肝口服新藥的CP值相
健保給付條件嚴 健保署:6月將放寬條件 傳統治療以干擾素為主,治癒率也不差,約有七、八成,
C肝口服新藥治癒率超過九成 注意肝毒性、謹慎用藥、定期回診 王昶皓醫師指出,目前健保給付兩款C肝口服新藥,
(浩鼎案 開庭) 翁啟惠…技術授權 廠商冒風險 怎麼會有行賄呢?
浩鼎案開庭 翁啟惠:我被誤解了 2017-05-0313:54 [記者黃捷/台北報導]前中研院長翁啟惠、
(瑞士Dr. Zuber分享) 麗臺 開發 ”心電心音檢測”
麗臺科技邀請瑞士心臟名醫分享心音穿戴裝置於臨床應用【CTIM
(澄清) 台康Herceptin生物相似藥 分食66億美金
台康生技 發言日期106/05/03發言時間11:16:11 發言人劉理成發言人職稱總經理發言人電話(02)7708-